Finally, using RNAi and CRISPR/Cas9 gene editing we demonstrated that reduction or complete knockout of TM9SF2 resulted in reduced tumor fitness in the in vitro and in vivo settings. This evidence concerns the gene TM9SF2 and neoplasm.